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Objectives: Inflammation is the most important
mechanism of plaque disruption playing an essential
role in acute coronary syndromes. It is controversial
whether the inflammatory mediators are the cause or
the result in the development of plaque rupture.
Stimulation of interleukins increases adhesion mole-
cules, fibrinogen and plasminogen activator inhibi-
tors, which cause the activation of inflammation and
thrombosis. However, the importance of interleukins
in acute coronary syndromes has not been clearly
defined. We did not find any article concerning
relations between the levels of serum interleukin
(IL)-1b, IL-2, IL -8 and tumor necrosis factor (TNF)-a in
patients with unstable angina pectoris (UAP). So the
aim of this study was to determine the levels of serum
IL-1b, IL-2, IL-8 and TNF-a during the early stage of
UAP.
Methods and results: Thirty-seven patients with UAP
(12 females and 25 males; mean age, 57.59 /9.7 years)
within 6 h of admission and 20 healthy volunteers
(eight females and 12 males; mean age, 51.39 /6.3
years) were included in the study. IL-1b, IL-2, IL-8 and
TNF-a levels were measured using the enzyme-linked
immunosorbent assay method. Patients with acute or
chronic inflammation, renal failure or chronic heart
failure were excluded from the study. The age, gender
and risk factors of the study and control groups were
similar. The levels of IL-1b, IL-8 and TNF-a were
significantly increased (p B/0.0001, p B/0.001 and
p B/0.016, respectively) in patients with UAP. There
was no difference of IL-2 levels between the UAP
group and controls.
Conclusion: We detected high levels of IL-1b, IL-8 and
TNF-a in patients with UAP during early phase. We
suggest that proinflammatory cytokines (e.g. IL-1b,
IL-8, TNF-a) may play an important role in the
development of atherosclerosis and its complica-
tions.
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Introduction
Atherosclerosis is currently one of the main causes of
death. A great majority of deaths related to athero-
sclerosis occur due to acute complications, mainly
based on plaque disruption.
1,2 Inflammation is the
most important mechanism of plaque disruption of
which it is crucial to reveal the molecular mechan-
isms.
3,4
Previously, the appearance of immune cells at the
ischemic site of myocardial tissue was believed to be
a response to tissue injury. Inflammatory processes
are now recognized to play a central role in the
pathogenesis of atherosclerosis and its complications.
A growing body of evidence suggests that unstable
angina is associated with local and systemic activa-
tion of the immune system. Plasma levels of several
inflammation markers have been found to be asso-
ciated with future cardiovascular risk in a variety of
clinical settings. These markers include cell adhesion
molecules, cytokines, pro-atherogenic enzymes and
C-reactive protein (CRP).
5
Circulating markers may consist of cytokines
directly released from inflammatory cells present in
the plaques and tissues exposed to recurrent ische-
mia as well as other reactants produced in response
to these cytokines such as adhesion molecules and
acute phase proteins. Recent studies suggest that
markers of inflammation may reflect different aspects
of the atherothrombotic process at different points in
the continuum of acute coronary syndromes (ACS).
Inflammatory markers have a potential role for the
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361prediction of risk for developing coronary artery
disease (CAD), and could correlate with severity
and future risk for CAD.
6
Inflammation markers such as CRP, fibrinogen and
cytokines have been implicated in the development
and progression of CAD.
7 13 However, their role in
the development of ACS has not been clearly defined.
We did not find any article concerning the relations
between the levels of serum interleukin (IL)-1b, IL-2,
IL-8 and tumor necrosis factor (TNF)-a in patients
with unstable angina pectoris (UAP). So the aim of
this study is to determine the levels of serum IL-1b,
IL-2, IL-8 and TNF-a during the early stage of UAP.
Materials and methods
Patients with new onset, Braunwald Class III resting
angina within 6 h, but not preceding acute myocar-
dial infarction, were considered as having UAP and
were included in the study (12 females and 25 males;
mean age, 57.59 /9.7 years). The study group did not
take any medicine and had a fairly unremarkable
medical history. Twenty patients (eight females and
12 males; mean age, 51.39 /6.3 years) with normal
coronary arteries on angiogram were considered the
control group. Patients with evidence of any infec-
tious disease, significantly higher erythrocyte sedi-
mentation rate ( /20 mm/h), high fever (]/38.38C),
immunological disorders, neoplastic diseases, chest
pain lasting more than 6 h and normal coronary
arteries were not included in the study. Finally, 37
patients remained in the UAP group.
All of the patients with UAP were hospitalized and
their medications were initiated accordingly. All
patients received acetyl salicylic acid, b-blocker,
weight-adjusted low molecular weight heparin and
lipid lowering therapy. Thirty-seven patients enrolled
in the study underwent coronary angiography. Sig-
nificant CAD was defined as more than 50% narrow-
ing of the luminal diameter in a major epicardial
vessel. Blood samples were obtained from the UAP
group on admission (within a maximum 6 h after the
onset of pain) before angiographic investigation, to
reveal biochemical parameters and interleukin levels.
Blood samples were centrifuged at 5000 rpm for 5
min and the collected serum samples were stored at
 /808C for a maximum time period of 1 month. IL-1b,
IL-2, IL-8 and TNF-a kits were purchased from R&D†
(Roche Diagnostics, USA) and Biosource (USA), and
the results were interpreted according to the instruc-
tions given by the manufacturer.
All data are presented in the format of the mean9 /
standard deviation. Comparisons between two
groups were performed using a parametric one-way
analysis of variance test. pB/0.05 was considered
statistically significant.
Results
Age, gender, and risk factors (e.g. smoking, lipid
profiles, hypertension, and diabetes mellitus) of the
patients are presented in Table 1. There was no
statistically significant difference between study and
control groups.
In the group of UAP, the levels of IL-1b, IL-8 and
TNF-a were significantly increased (pB/0.0001, p B/
0.001, p B/0.016 and p B/0.05, respectively) (Table 2).
There was no difference of IL-2 levels between the
UAP group and the control group.
Discussion
Recently, the role of inflammation in the pathogen-
esis of atherosclerosis has been understood better. By
means of acute phase reactants, interleukins increase
both inflammation and smooth muscle hyperpla-
sia.
14,15 Interleukins, which are soluble hormone-
like protein substances, mediate the functions of
message production and interaction between im-
mune system cells and determine the immune
response.
Stimulation of interleukins increase adhesion mo-
lecules, and fibrinogen and plasminogen activator
Table 1. Characteristics of patients
UAP group
(n /37)
Control group
(n /20)
p value
Age (years) 589 /10 519 /6N S
Sex 25 male/
12 female
12 male/
8 female
NS
Smokers (%) 24(65) 12(60) NS
Hypertension (%) 16(43) 8(40) NS
Diabetes mellitus (%) 9(24) 4(20) NS
Heredity (%) 8(21) 3(15) NS
Total cholestrol 2019 /40 1969 /31 NS
Low-density lipoprotein cholestrol 1469 /27 1359 /26 NS
High-density lipoprotein cholestrol 329 /63 7 9 /6N S
Triglyceride 2129 /95 1439 /64 NS
NS, Not significantly different.
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stimulation of thrombosis.
16 Ischemia causes release
of TNF-a and IL-1b from mononuclear cells. It has
been proved that there are elevated levels of inter-
leukins in serum of patients with UAP, which carry
proinflammatory and procoagulant properties and
the degree of elevation of the interleukin level is
related to prognosis.
17
Interleukin-1b
IL-1b is produced largely by activated macrophages,
endothelial cells, and also by vascular smooth muscle
cells.
18,19 IL-1b actively participates in the regulation
of vascular cell functions, including the stimulation of
leukocyte adhesion to the endothelial cells, perme-
ability of vessels, matrix metalloprotease production,
suppression of vascular contractility, regulation of the
pathways of coagulation within the cell and the
production of procoagulator.
16 It is clear that its
levels increase during ischemic heart disease. IL-1b
contributes to the development of atherosclerosis.
Simon et al.
20 stated that there was a significant
increase in IL-1b values in UAP patients compared
with stable angina patients.
We found statistically significant increase in IL-1b
levels of the study group. The effect of IL-1b on acute
process was not clear. IL-1b might be responsible for
plaque rupture and triggering ACS. However, IL-1b
could be released from the vascular endothelium or
ischemic myocardium. Since we could measure IL-1b
only at admission, we could not differentiate the
source of this increase. In addition to CRP evaluation,
we suggest that IL-1b levels could be used for
detection of high-risk patients.
Interleukin-2
In normal conditions immunologic response does not
show IL-2 within circulation. IL-2 causes angiogen-
esis. All IL-2, IL-4, IL-6 and TNF-a can induce release
of IL-2 and its receptors. IL-2 has a central role in the
development of cell-mediated immunity and also it
serves as a key factor in the induction of a complex
network of cytokines.
21
Mazzone et al.
22 showed that IL-2 levels increased
in patients with CAD, but no significant increase was
observed in ACS. Takeshita et al.
23 found that serum
IL-2 receptors were significantly lower in ACS com-
pared with control. Mizia-stec et al. reported that
patients with CAD, irrespective of the form of the
disease, have higher serum levels of pro-inflamma-
tory and anti-inflammatory cytokines than control
subjects. Increased concentrations of IL-2 in UAP may
suggest additional immunologic activation.
24 On the
contrary, levels of IL-2 and IL-2 receptors were
reported to be elevated significantly in patients with
stable angina, but not in patients with UAP.
25
In our study, the UAP group revealed a lower but
not statistically significant level of IL-2 compared with
the control group. This result seems to be in
accordance with the study of Simiti et al.
25 Since IL-
2 is an anti-inflammatory cytokine, we thought that it
might be downregulated first, and later on reaches
near normal levels in the early stages of ACS. We
measured IL-2 levels only at admission, so we cannot
estimate the profile of IL-2 levels. The role of IL-2 on
ACS has not been clearly defined as the results of
previous studies are contradictory. Further studies are
necessary in this issue.
Interleukin-8
Mononuclear cells, fibroblasts, endothelial cells, ker-
atinocytes and thrombocytes synthesize IL-8. Its
synthesis is stimulated by IL-1 and TNF-a. Chemo-
tactic features of IL-1 and TNF-a are mediated by IL-8,
which is a crucial chemokine known to attract and
activate neutrophils as well as T lymphocytes, and to
control their interaction. There are only a few studies
in the literature on the IL-8 levels in patients with
myocardial infarction. Simiti et al. reported that the
increased plasma IL-8 levels within the first 24 h after
the spontaneous episode of angina could represent a
marker of primary UAP, Braunwald’s class III-B. But
the plasma IL-8 levels do not increase in stable
angina.
25
Qi et al. demonstrated that plasma IL-8 levels
increase as a reflector of the abnormal coagulation
activity in patients with UAP after coronary angio-
plasty.
26 Miya et al. reported that IL-8 seems to have
a role in the pathogenesis of acute coronary artery
thrombi. This hypothesis leads us to test those
interventions on the influence of IL-8 secretion in
the early phase of coronary thrombus formation.
27 In
the literature on the pathologic and biochemical
investigations of the atherosclerotic coronary pla-
ques, it has been stated that the level of IL-8 increased
as an angiogenic factor.
27 29
In our study, the levels of IL-8 in UAP cases were
found significantly increased compared with normal
healthy subjects. Our results are in accordance with
literature clues. We suggest that IL-8 has an important
role in inflammation and coagulation in UAP cases.
We did not conclude any definitive relationship
Table 2. Levels of serum IL-1b, 1L-2, 1L-8 and TNF-a
UAP group
(n /37)
Control group
(n /20)
p value
IL-1b (ng/dl) 3789 /34 119 /14 B/0.0001
IL-2 (ng/dl) 119 /14 159 /19 NS
IL-8 (ng/dl) 4189 /506 879 /154 B/0.001
TNF-a (ng/dl) 1009 /201 199 /9 0.016
Values are expressed as mean9 /standard deviation. NS, Not
significantly different.
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lation status, since we did not measure them.
Tumor necrosis factor-a
TNF-a plays a role in the processes of coagulation,
ischemia and reperfusion injury. TNF-a may have a
certain role in the development of ischemia by
causing release of endothelial adhesion molecules,
activation of leukocytes and secretion of thrombocyte
activating factors. Endothelial cells are highly sensi-
tive to TNF-a. By the effect of TNF-a the production
of adhesion molecules and procoagulants increases,
whereas the synthesis of protein-C is suppressed.
30
Proving the high serum levels of TNF-a following
acute myocardial infarction observed in animal
models, TNF-a has been suspected to be related
with acute myocardial infarction pathogenesis.
30
Koukkunen et al. reported that a 3.5-fold increase
was observed in fibrinogen and TNF-a. They sug-
gested two underlying sources of events; the first is
the ‘inflammation’ factor that includes CRP, fibrino-
gen and IL-6, and the second is the ‘injury’ factor that
includes troponin-T, creatine kinase-MB mass and
TNF-a. Both of these factors were independent
predictors of the risk of coronary death and other
major coronary events. Both TNF-a and IL-6 were
elevated in the coronary sinus compared with the
aortic root in patients with UAP. There is an
intracardiac inflammatory response in UAP that
appears to be the result of low-grade myocardial
necrosis. Mizia-stec et al. stated that serum concen-
trations of TNF-a were significantly higher in patients
with CAD than in the control group.
24
In our study, TNF-a was significantly higher in the
study group than in the control group. Although we
did not measure troponin, we speculated that this
increase might be associated with microinfarcts in
UAP patients. Thus, we thought that elevated TNF-a
could be used for risk stratification.
Limitations of this study
Unfortunately, our study contained a relatively small
number of patients to reach an exact conclusion. This
situation is valid especially for evaluations of IL-8 and
IL-2 levels. Another limitation was that we accepted
the chest pain commencement time within 6 h
(approximately 4.89 /1.2 h) for the UAP group.
Some factors such as taking serum samples at
admission of the patients with UAP and changes of
cytokines according to time passed, not measuring
the troponin level that is an indicator of microinfarcts
in patients with UAP and high-risk patients, and not
determining its relation to other related parameters
are the other restrictions.
In conclusion, we suggest that IL-1b, IL-8 and TNF-
a are directly involved in the triggering stage of acute
coronary events. As for CRP, high levels of inflam-
matory cytokines such as IL-1b and TNF-a may be
used for determining the high-risk patients in UAP.
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